In addition to the previously mentioned PSMA-PET exclusion criteria, the TheraP trial excluded patients with FDG-positive, PSMA-negative disease [5], given that PSMA-negative disease is not sufficiently targeted by LuPSMA therapy and may represent aggressive clones of prostate cancer, which might have undergone dedifferentiation or neuroendocrine transdifferentiation [19, 22, 23]. Here, FOLH1 is linked to prostate cancer.